Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum

460

Prithviraj Bose,[1] Nico Gagelmann,[2] Vikas Gupta,[3] Donal P. McLornan,[4] Pankit Vachhani,[5] Hafia Kathrin Al-Ali,[6] Haris Ali,[7] Philipp Treskes,[8] Sarah Buckley,[8] Karisse Roman-Torres,[8] Bart Scott[9]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX, [2]University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [3]Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; [4]University College London Hospitals NHS Foundation Trust, London, UK; [5]O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, AL; [6]Krukenberg Cancer Center, University Hospital Halle, Halle, Germany; [7]City of Hope National Medical Center, Duarte, CA; [8]CTI BioPharma Corp., a Sobi company, Seattle, WA; [9]Fred Hutchinson Cancer Research Center, Seattle, WA

INTRODUCTION

- In patients with myelofibrosis (MF), JAK inhibitor therapy can improve both splenomegaly and disease symptoms.
- Commonly, dosing – and thus efficacy – of JAK1/2 inhibitors is limited in patients with cytopenic MF due to drug-induced exacerbation of cytopenias.[1,2]
- Pacritinib is a JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1[3,4] that is approved by the Food and Drug Administration (FDA) in the United States for the treatment of adults with myelofibrosis who have a platelet count <50 x 10^9/L.
- Clinical studies of pacritinib have included patients across the cytopenic spectrum, including any grade of baseline (BL) anemia or thrombocytopenia.[5-7]

AIMS

- To describe the dosing and efficacy of pacritinib in patients with MF treated across two clinical trials (PERSIST-1 and PERSIST-2), stratified by degree of baseline thrombocytopenia and anemia.

METHODS

- Evaluable patients treated with pacritinib in the PERSIST-1 and PERSIST-2 studies were analyzed, stratified by baseline blood counts (5 subgroups):
  - Platelet count: <100 and ≥100 x10^9/L
  - Hemoglobin: <8, 8 to <10, and ≥10 g/dL
- Efficacy was assessed with the following metrics:
  - Spleen volume reduction (SVR) at week 24 based on 4 different response thresholds (>0%, ≥10%, ≥25%, and ≥35%) and median percent change in spleen volume over time
  - Total symptom score (v2.0 [excluding tiredness], TSS) response at week 24 based on 4 different response thresholds (>0%, ≥10%, ≥25%, and ≥50%) and median percent change in TSS over time
  - Anemia benefit was analyzed in the subgroup with baseline HB <8g/dL, including changes in HB over time and RBC transfusion independence (TI), defined as zero transfusion over any 12-week period.
- Median change in hemoglobin (and interquartile range) was presented by baseline hemoglobin across the study follow-up visits.

RESULTS


Table 1. Baseline Patient and Disease Characteristics

Characteristics	PAC (pooled) N=276
Median age, years	67
Primary myelofibrosis, n (%)	192 (70%)
Grade 3 reticulin fibrosis	142 (51.5%)
Prior JAK inhibitor, n (%)	44 (16%)
Median palpable spleen length, cm	12.00
Baseline PLT count <100 x10^9/L, n (%)	136 (49%)
Baseline PLT count ≥100 x10^9/L, n (%)	137 (50%)
Baseline HB <8 g/dL, n (%)	29 (10.5%)
Baseline HB 8 to <10 g/dL, n (%)	94 (34%)
Baseline HB ≥10 g/dL, n (%)	153 (55%)

BID, twice daily; HB, hemoglobin, JAK, Janus associated kinase; PAC, pacritinib; PLT, platelets.

- Among 276 evaluable patients, 70% had primary MF, 51.5% had grade 3 reticulin fibrosis, and 16% had prior JAK2 inhibitor exposure (**Table 1**).
- Across PLT and HB strata:
  - 75.5-82% achieved SVR≥10
  - 84-93% achieved any spleen reduction (SVR>0) (**Figure 1**).
- The depth of week 24 spleen reduction was consistent across all analyzed PLT and HB strata.
- Spleen reduction occurred by week 12 across all subgroups and remained consistent over time (**Figure 1**).


Figure 1. Spleen Volume Response Over Time by Baseline Blood Counts



IQR, interquartile range.

- Any improvement in symptoms (TSS>0) occurred in 80-87.5% of patients across all cytopenia groups.
  - TSS≥50 occurred at the highest rate (62.5%) in patients with a baseline hemoglobin <8 g/dL
  - Improvement in TSS was observed by week 12 with ongoing improvement sustained through week 36, particularly in patients with baseline hemoglobin <8 g/dL (**Figure 2**).

Figure 2. Total Symptom Score (TSS) Response Over Time by Baseline Blood Counts




IQR, interquartile range.

- Roughly half of the patients in each subgroup reported their disease symptoms as "much" or "very much" improved at week 24.

RESULTS


Figure 3. TSS Subscale Responses by Baseline HB Counts



IQR, interquartile range.

- All HB subgroups observed reductions in the TSS subscales (physical function, cytokine-related, and spleen-related), with the HB <8 g/dL group showing the greatest reduction (**Figure 3**).
- Patients across all hemoglobin subgroups (**Figure 4a, b, c**) maintained a median dose intensity of 100%.


Figure 4. Dose Intensity of Patients on Pacritinib by Baseline HB Counts



HB, hemoglobin; PLT, platelet.

- Median hemoglobin remained stable through week 24 (**Figure 6**), with some improvement in the subgroup with baseline hemoglobin <8 g/dL.

Figure 5. Median Change in Hemoglobin Over Time by Baseline Hemoglobin (HB) Subgroups



N								
	0	3	4	8	12	16	20	24
HB≥10 g/dL	153	141	144	148	147	150	150	143
HB≥8 to <10 g/dL	94	85	83	90	91	91	93	82
HB<8 g/dL	29	26	26	26	27	29	27	24

IQR, interquartile range.

- Subgroups with less severe anemia had stable HB levels over time
- Of 29 patients with baseline HB <8 g/dL, 90% (n=26) were receiving RBC transfusions at baseline.
  - 35% (n=9/26) became transfusion independent (TI) on study.
- Among the patients with hemoglobin <8 g/dL who met Gale criteria for transfusion dependence at baseline, 23% (n=3/13) became TI on study.
- A modest correlation between percent improvement in hemoglobin and percent decrease in tiredness from baseline to week 24 was observed (r -0.33, *P*=0.15) in patients with baseline HB <8 g/dL.

CONCLUSIONS

- Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of baseline blood counts.
- Patients with more severe anemia experienced hematologic improvement and transfusion independence
- This consistent effect may be related to pacritinib's unique mechanism of action and its ability to be delivered at full dose in patients regardless of cytopenias.

ACKNOWLEDGEMENTS: This study is supported by CTI BioPharma Corp., a Sobi company, and was previously presented by Dr. Nico Gagelmann at EBMT 2023 and Dr. Prithviraj Bose at ASCO 2023.

REFERENCES: 1. Harrison et al. *Leukemia*. 2016;30;1701-1707. **2.** Harrison et al. *Lancet Hematol*. 2017;4:e317-e324. **3.** Singer et al. *J Exp Pharmacol*. 2016;8:11-19. **4**. Oh et al. *Clin Lymphoma Myeloma Leuka*. 2022;S:327 **5**. Mesa et al. *Lancet Haematol*. 2017;4:e225-e236. **6.** Mascarenhas et al. *JAMA Oncol*. 2018;4:652-659. **7**. Gerds et al. *Blood Adv*. 2020;4:5825-5835.

Disclosures: PB has consulted for AbbVie, and Karyopharm; has consulted for and received honoraria from Blueprint, BMS, Cogent, CTI BioPharma Corp., a Sobi company, GSK, Incyte, Jubilant, Karyopharm, Morphic, MorphoSys, Novartis, PharmaEssentia, and Sumitomo; has received honoraria and research funding from Blueprint, BMS, Cogent, CTI BioPharma Corp., a Sobi company, Incyte, and MorphoSys; and has received research funding from Blueprint, BMS, Cogent, CTI BioPharma Corp., a Sobi company, Disc Medicine, Geron, Incyte, Ionis, Janssen, Kartos, MorphoSys, Sumitomo, and Telios. **VG** has consulted for AbbVie, Celgene, CTI BioPharma Corp. a Sobi company, Galecto, Geron, GSK, Imago, Incyte, Kartos, Karyopharm, MorphoSys, Novartis, Pfizer, PharmaEssentia, Roche and Sierra Oncology; has received research funding from AbbVie, BMS, Celgene, CTI BioPharma Corp. a Sobi company, Geron, Incyte, Janssen, Kartos, Karyopharm, Merck, Novartis, PharmaEssenta and Roche; has participated in advisory boards for AbbVie, BMS, Celgene, Constellation, CTI BioPharma Corp. a Sobi company, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Merck, MorphoSys, Novartis, Pfizer, PharmaEssentia, Prelude Therapeutics and Roche. **DPMcL** has received speakers fees from AbbVie, BMS/Celgene, Jazz Pharmaceuticals and Novartis; has received research funding from BMS/Celgene and Jazz Pharmaceuticals; and has participated on advisory boards and received travel assistance from Jazz Pharmaceuticals. **PV** has received honoraria from AbbVie, Amgen, Blueprint Medicines, Cogent Biosciences, Incyte, CTI BioPharma., a Sobi company, Daiichi Sankyo, GSK, Karyopharm, Novartis, Pfizer, Genetech, Inc., Servier, Stemline, MorphoSys, and LAVA Therapeutics; and has participated in speaker's bureaus for Incyte, CTI BioPharma Corp., a Sobi company, and Blueprint Medicines. **HKA-A** has received research funding from BMS, Incyte and Novartis; has participated on advisory boards for AbbVie, AOP Pharma, Blueprint, BMS and Novartis; and has received travel assistance from AbbVie, BMS and Novartis. **HA** has participated on advisory committees for AbbVie, BMS, and Incyte; and has participated in a speakers bureau for Incyte. **PT** has consulted for CTI BioPharma Corp., a Sobi company. **SB** and **KR-T** are employed by and have received payment of unvested equity awards from CTI BioPharma Corp., a Sobi company. **BS** participated on the data and safety monitoring board for Nektar and Johnson and Johnson; has participated in advisory panels for BMS, Celgene, Jazz Pharmaceuticals, and Novartis; has consulted for Alexion, Celgene, BMS, and Incyte; has received honoraria from Celgene, and BMS; and has received research funding from BMS and Novartis.

Presenter: Dr. Prithviraj Bose; PBose@mdanderson.org